Irinotecan

Bone Neoplasm

Actuate Therapeutics Inc.Small moleculePhase 3Active

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 51/ 100
Competitive Position: 95/ 100

Competitive context

4 Active assets in the Bone Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Zoledronate AstraZeneca	Phase 4	BB
Pregabalin Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 4	BB
Saracatinib AstraZeneca	Phase 2	B
Gemogenovatucel-T Gradalis, Inc.	Phase 3	B
Lomustine Actuate Therapeutics Inc.	Phase 2	CCC

View all 16 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerActive

BBB

Indicative · Phase 4

78 / 100

exocrine pancreatic carcinomaActive

BBB

Indicative · Phase 2/3

78 / 100

colon adenocarcinomaActive

BBB

Indicative · Phase 3

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.